Biomed & Biotech Firms - Publicly Traded*

Halozyme Therapeutics

Company Website

11388 Sorrento Valley Rd.
San Diego, CA 92121

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Halozyme Therapeutics

Market Cap as of 6/12/2015

$2,639,377,920

Market Cap as of 7/03/2014

$1,269,989,739

Market Cap as of 07/02/2013

$932,445,740

Market Cap as of 06/26/2012

$980,067,627

Market Cap as of 01/04/2012

$959,147,700

Market Cap as of 06/20/2011

$677,485,300

Market Cap as of 01/06/2011

$789,418,400

Exchange and Ticker Symbol

Nasdaq: HALO

Fields of Research

Research focuses on human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits

Major Products

Enhanze technology, Ultrafast Insulin program, PEGPH20, HTI-501

Executives

Jonathan Lim (profile)

  • Former CEO

Gregory Frost

  • Chief Executive Officer

Greg Frost

  • Chief Executive Officer

Gregory Frost

  • Co-Founder
  • President

Greg Frost

  • President